All In Biotech

Drug Trial Radar · NCT07136285

Olvi-Vec Combined With Platinum Plus Etoposide Therapy in Patients With Late Phase SCLC

PIb/II, Open-label, Multicenter Study to Evaluate the Safety, Tolerability and Efficacy of I.V. Olvi-Vec Combined With Platinum Plus Etoposide in Patients With Advanced SCLC Who Are Platinum-recurrent or Platinum-refractory

Last checked: Nov 19, 2026Latest source record: Dec 3, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

27

Planned (sponsor's estimate)

Start

Jul 24, 2023

Primary completion

Dec 2026

Study completion Dec 2026

Sponsor

Sponsor type
Industry
Collaborators
Genelux Corporation
First posted
Aug 22, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Oncolytic virus product named Olvi-Vec combined with Platinum plus Etoposide in patients with late phase SCLC

Conditions

  • SCLC, Extensive Stage

Interventions

  • Olvi-VecDrug

    Olvi-Vec will be administered to patient for 3 days during C1

  • platinum (cisplatin or carboplatin)Drug

    After completing the first cycle of treatment of Olvi-Vec (+21 days after the last dose), Platinum (Carboplatin or Cisplatin)will be administrated on D1,D2 and D3 each 21 days (dosage according to the label) from Cycle 2 until disease progression or intolerable toxicity occurred.

  • EtoposideDrug

    After completing the first cycle of treatment of Olvi-Vec (+21 days after the last dose), Etoposide will be administrated on D1,D2 and D3 each 21 days (dosage according to the label) from Cycle 2 until disease progression or intolerable toxicity occurred.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Evaluate safety of Olvi-Vec in patients from day 1 to end of studyTime frame: Interval between the date of enrollment and the date of withdraw and completion of study, up to a maximum of 2 years.

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Zhejiang Provincial People's Hospital

    Hangzhou, China · Recruiting

  • Shanghai chest hospital

    Shanghai, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.